Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an antimetabolite immunosuppressant presented as an enteric‑coated tablet for oral use. It is used to prevent organ rejection in transplant recipients.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfortic is an antimetabolite immunosuppressant used in transplantation to inhibit lymphocyte proliferation.

- Renal transplantation: helps prevent graft rejection in kidney transplant patients. - Heart transplantation: helps prevent graft rejection in heart transplant patients. - Liver transplantation: helps prevent graft rejection in liver transplant patients.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort. - Headache: persistent or intermittent. - Tremor: fine shaking of hands. - Infections: increased susceptibility to common infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count. - Severe infections: opportunistic or life‑threatening infections. - Hepatic dysfunction: abnormal liver enzyme elevations. - Malignancy: increased risk of certain cancers. - Progressive multifocal leukoencephalopathy: rare brain infection.

Patients receiving Myfortic should be monitored closely for safety and efficacy.

- Monitor blood counts: check complete blood count regularly. - Monitor renal function: assess serum creatinine and glomerular filtration rate. - Monitor liver enzymes: evaluate hepatic function periodically. - Pregnancy warning: avoid use during pregnancy (Category D) unless benefits outweigh risks. - Adjust in hepatic impairment: dose may need modification in liver disease. - Avoid live vaccines: immunosuppression can reduce vaccine effectiveness. - Store at ambient temperature: keep in the original pack, protect from moisture.

Myfortic may interact with several medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Cyclosporine: increases mycophenolic acid exposure, raising toxicity risk. - Tacrolimus: similar increase in exposure, may require dose reduction. - Antacids/colestyramine: bind the drug and reduce absorption. - Rifampin: induces metabolism, markedly lowering drug levels. - Hormonal contraceptives: may reduce efficacy, consider alternative methods.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression, monitor blood counts. - NSAIDs: increased risk of nephrotoxicity, watch renal function. - ACE inhibitors/ARBs: potential for hyperkalemia, monitor electrolytes. - Live vaccines: reduced effectiveness, assess risk/benefit. - Proton‑pump inhibitors: may modestly affect absorption, observe clinical response.